作者
Christof M Kazda, Ying Ding, Ronan P Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, David E Watson, Andrew J Lewin, William H Landschulz, Mark A Deeg, David E Moller, Thomas A Hardy
发表日期
2016/7/1
期刊
Diabetes Care
卷号
39
期号
7
页码范围
1241-1249
出版商
American Diabetes Association
简介
OBJECTIVE
Type 2 diabetes pathophysiology is characterized by dysregulated glucagon secretion. LY2409021, a potent, selective small-molecule glucagon receptor antagonist that lowers glucose was evaluated for efficacy and safety in patients with type 2 diabetes.
RESEARCH DESIGN AND METHODS
The efficacy (HbA1c and glucose) and safety (serum aminotransferase) of once-daily oral administration of LY2409021 was assessed in two double-blind studies. Phase 2a study patients were randomized to 10, 30, or 60 mg of LY2409021 or placebo for 12 weeks. Phase 2b study patients were randomized to 2.5, 10, or 20 mg LY2409021 or placebo for 24 weeks.
RESULTS
LY2409021 produced reductions in HbA1c that were significantly different from placebo over both 12 and 24 weeks. After 12 weeks, least squares (LS) mean change from baseline in HbA …
学术搜索中的文章
CM Kazda, Y Ding, RP Kelly, P Garhyan, C Shi, CN Lim… - Diabetes Care, 2016